The Australian Obesity Management Algorithm: A simple tool to guide the management of obesity in primary care
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Obesity is a complex and multifactorial chronic disease with genetic, environmental, physiological and behavioural determinants that requires long-term care. Obesity is associated with a broad range of complications including type 2 diabetes, cardiovascular disease, dyslipidaemia, metabolic associated fatty liver disease, reproductive hormonal abnormalities, sleep apnoea, depression, osteoarthritis and certain cancers. An algorithm has been developed (with PubMed and Medline searched for all relevant articles from 1 Jan 2000–1 Oct 2021) to (i) assist primary care physicians in treatment decisions for non-pregnant adults with obesity, and (ii) provide a practical clinical tool to guide the implementation of existing guidelines (summarised in Appendix 1) for the treatment of obesity in the Australian primary care setting. Treatment pathways should be determined by a person’s anthropometry (body mass index (BMI) and waist circumference (WC)) and the presence and severity of obesity-related complications. A target of 10–15% weight loss is recommended for people with BMI 30–40 kg/m2 or abdominal obesity (WC > 88 cm in females, WC > 102 cm in males) without complications. The treatment focus should be supervised lifestyle interventions that may include a reduced or low energy diet, very low energy diet (VLED) or pharmacotherapy. For people with BMI 30–40 kg/m2 or abdominal obesity and complications, or those with BMI > 40 kg/m2 a weight loss target of 10–15% body weight is recommended, and management should include intensive interventions such as VLED, pharmacotherapy or bariatric surgery, which may be required in combination. A weight loss target of > 15% is recommended for those with BMI > 40 kg/m2 and complications and they should be referred to specialist care. Their treatment should include a VLED with or without pharmacotherapy and bariatric surgery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“8 mg daily in people with type 2 diabetes improved cardiovascular outcomes compared with placebo [34], no differences in cardiovascular risk were shown in a post hoc analysis of data from 5 trials (n = 5908 participants) using the 3 mg daily dose compared to placebo [35].”
BackgroundOnce-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 2×
“• Semaglutide and lifestyle: average weight loss 15% at 68 weeks [42] Bariatric surgery with maintained lifestyle changes > 15% weight loss consistently across studies; weight loss likely to be maintained > 5 years”
BackgroundDiabetes Prevention Program Research Group (2009) · The Lancet · doi:10.1016/s0140-6736(09)61457-4 · Cited by 3,020
Congenital leptin deficiency is associated with severe early-onset obesity in humans
Montague, C. T., Farooqi, I. S., Whitehead, J. P., Soos, M. A., Rau, H., Wareham, N. J., Sewter, C. P., Digby, J. E., Mohammed, S. N., Hurst, J. A., et al. (1997) · Nature · doi:10.1038/43185 · Cited by 2,936
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Lean, M. E., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Peters, C., Zhyzhneuskaya, S., Al-Mrabeh, A., Hollingsworth, K. G., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33102-1 · Cited by 2,095 · cited 2×
“3 DiRECT [23], which enroled only subjects with type 2 diabetes (of up to six years’ duration), 46% were in remission at 12 months and 36% were still in remission at two years [24].”
BackgroundComparison of Weight-Loss Diets with Different Compositions of Fat, Protein, and Carbohydrates
Sacks, F. M., Bray, G. A., Carey, V. J., Smith, S. R., Ryan, D. H., Anton, S. D., McManus, K., Champagne, C. M., Bishop, L. M., Laranjo, N., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0804748 · Cited by 1,966 · cited 1×
“Similar weight loss can be achieved with diets of different macronutrient content [17,18].”
BackgroundRoss, R., Neeland, I. J., Yamashita, S., Shai, I., Seidell, J., Magni, P., Santos, R. D., Arsenault, B., Cuevas, A., Hu, F. B., et al. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0310-7 · Cited by 1,966 · cited 1×
“Consistency of the method used is important as values differ with each technique [46].”
MethodXENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study
Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.155 · Cited by 1,915 · cited 2×
“Study results: • Orlistat and dietary change: average weight loss 6–10 kg at 12 months; 2–3 kg at 5 years [31]”
BackgroundResultObesity in Young Men after Famine Exposure in Utero and Early Infancy
Ravelli, G.-P., Stein, Z. A., & Susser, M. W. (1976) · New England Journal of Medicine · doi:10.1056/nejm197608122950701 · Cited by 1,647 · cited 1×
“There is strong evidence that obesity is predominantly genetic [5,6] caused by classical genetic mutations [7–9] and epigenetic mechanisms [10,11].”
Background
Cited by
Contemporary medical, device, and surgical therapies for obesity in adults
Perdomo, C. M., Cohen, R. V., Sumithran, P., Clément, K., & Frühbeck, G. (2023) · The Lancet · doi:10.1016/s0140-6736(22)02403-5 · Cited by 738
Strengths and Limitations of BMI in the Diagnosis of Obesity: What is the Path Forward?
Sweatt, K., Garvey, W. T., & Martins, C. (2024) · Current Obesity Reports · doi:10.1007/s13679-024-00580-1 · Cited by 398
“…care beginning with American Association of Clinical Endocrinology (AACE) [90], European Association for the Study of Obesity (EASO) [91], the Australian [92] and Canadian [93] guidelines and those advocated by the Obesity Medical Association (https://obesitymedicine.org/obesity-algo-rithm/).”
BackgroundWhat is the pipeline for future medications for obesity?
Melson, E., Ashraf, U., Papamargaritis, D., & Davies, M. J. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01473-y · Cited by 332
Wharton, S., Freitas, P., Hjelmesæth, J., Kabisch, M., Kandler, K., Lingvay, I., Quiroga, M., Rosenstock, J., & Garvey, W. T. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00226-8 · Cited by 119
Recent progress in the pharmacotherapy for obesity
Lu, J., Liu, P., Cai, M., Lv, T., Zhang, M., Yin, K., Cheng, J., & Zhang, G. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177850 · Cited by 17
Metadata
- Authors
- Markovic, T. P., Proietto, J., Dixon, J. B., Rigas, G., Deed, G., Hamdorf, J. M., Bessell, E., Kizirian, N., Andrikopoulos, S., & Colagiuri, S.
- Venue
- Obesity Research & Clinical Practice
- Publisher
- Elsevier BV
- Published
- 2022-09
- Volume
- 16
- Issue
- 5
- Pages
- 353-363
- ISSN
- 1871-403X (ISSN-L)
- OpenAlex
- W4293724319
- Cited by
- 71
- References
- 25
- FWCI
- 6.66
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Australian Obesity Management Algorithm: A simple tool to guide the management of obesity in primary care. https://app.cochat.ai/papers/10.1016/j.orcp.2022.08.003
- The paper
- Markovic, T. P., Proietto, J., Dixon, J. B., Rigas, G., Deed, G., Hamdorf, J. M., Bessell, E., Kizirian, N., Andrikopoulos, S., & Colagiuri, S. (2022). The Australian Obesity Management Algorithm: A simple tool to guide the management of obesity in primary care. Obesity Research & Clinical Practice. https://doi.org/10.1016/j.orcp.2022.08.003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.